The successful pre-NDA meeting for FILSPARI could be a positive catalyst for TVTX's stock as it moves closer to potential FDA approval for IgAN treatment. However, the uncertainty around the regulatory path for FSGS treatment could offset some of the positive sentiment. The workforce reduction is a cost-saving measure, which could be viewed positively by investors in terms of financial stability, but it also reflects potential challenges ahead.